30 years of historical data (1996–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vertex Pharmaceuticals Incorporated trades at 32.4x earnings, 23% above its 5-year average of 26.4x, sitting at the 75th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 37%. On a free-cash-flow basis, the stock trades at 39.5x P/FCF, 41% above the 5-year average of 27.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $126.2B | $117.0B | $103.9B | $106.0B | $74.8B | $57.1B | $62.3B | $57.1B | $42.9B | $37.9B | $18.0B |
| Enterprise Value | $124.8B | $120.7B | $101.0B | $96.4B | $65.2B | $51.2B | $57.2B | $54.6B | $40.9B | $36.9B | $17.7B |
| P/E Ratio → | 32.43 | 29.59 | — | 29.29 | 22.53 | 24.37 | 22.97 | 48.55 | 20.48 | 144.10 | — |
| P/S Ratio | 10.52 | 9.75 | 9.42 | 10.74 | 8.38 | 7.54 | 10.03 | 13.71 | 14.09 | 15.25 | 10.59 |
| P/B Ratio | 6.87 | 6.27 | 6.33 | 6.03 | 5.38 | 5.65 | 7.17 | 9.38 | 9.68 | 18.58 | 13.47 |
| P/FCF | 39.51 | 36.62 | — | 32.33 | 19.06 | 23.70 | 20.79 | 38.21 | 36.56 | 64.81 | 100.40 |
| P/OCF | 34.75 | 32.21 | — | 29.96 | 18.12 | 21.59 | 19.13 | 36.37 | 33.81 | 44.91 | 76.35 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Vertex Pharmaceuticals Incorporated's enterprise value stands at 26.6x EBITDA, 30% above its 5-year average of 20.5x. The Healthcare sector median is 13.8x, placing the stock at a 92% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.05 | 9.17 | 9.77 | 7.30 | 6.77 | 9.22 | 13.12 | 13.42 | 14.82 | 10.39 |
| EV / EBITDA | 26.63 | 25.74 | — | 24.03 | 14.64 | 17.62 | 19.28 | 41.88 | 57.78 | 199.79 | 247.89 |
| EV / EBIT | 26.63 | 25.74 | 362.01 | 21.80 | 15.21 | 18.36 | 18.01 | 37.58 | 60.78 | 688.12 | 1257.13 |
| EV / FCF | — | 37.78 | — | 29.41 | 16.62 | 21.28 | 19.10 | 36.57 | 34.80 | 63.00 | 98.49 |
Margins and return-on-capital ratios measuring operating efficiency
Vertex Pharmaceuticals Incorporated earns an operating margin of 39.1%. ROE of 22.5% indicates solid capital efficiency. ROIC of 22.8% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% |
| Operating Margin | 39.1% | 39.1% | -2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% |
| Net Profit Margin | 32.9% | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.5% | 22.5% | -3.2% | 23.0% | 27.7% | 24.9% | 36.7% | 22.4% | 64.7% | 15.6% | -9.2% |
| ROA | 16.4% | 16.4% | -2.4% | 17.7% | 21.0% | 18.6% | 27.0% | 16.2% | 42.8% | 8.2% | -4.2% |
| ROIC | 22.8% | 22.8% | -1.6% | 46.6% | 75.3% | 52.8% | 58.9% | 29.9% | 28.4% | 9.3% | 0.7% |
| ROCE | 23.0% | 23.0% | -1.2% | 22.2% | 32.3% | 26.3% | 33.9% | 19.8% | 16.2% | 5.1% | 0.5% |
Solvency and debt-coverage ratios — lower is generally safer
Vertex Pharmaceuticals Incorporated carries a Debt/EBITDA ratio of 0.8x, which is very conservative (75% below the sector average of 3.1x). Net debt stands at $3.7B ($3.7B total debt minus $5.1B cash). Interest coverage of 352.4x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.11 | 0.05 | 0.06 | 0.10 | 0.11 | 0.11 | 0.13 | 0.30 | 0.63 |
| Debt / EBITDA | 0.79 | 0.79 | — | 0.20 | 0.20 | 0.33 | 0.31 | 0.51 | 0.83 | 3.28 | 11.79 |
| Net Debt / Equity | — | 0.20 | -0.17 | -0.54 | -0.69 | -0.58 | -0.58 | -0.40 | -0.47 | -0.52 | -0.26 |
| Net Debt / EBITDA | 0.79 | 0.79 | — | -2.38 | -2.16 | -2.00 | -1.70 | -1.88 | -2.92 | -5.74 | -4.81 |
| Debt / FCF | — | 1.16 | — | -2.92 | -2.45 | -2.42 | -1.69 | -1.64 | -1.76 | -1.81 | -1.91 |
| Interest Coverage | 352.44 | 352.44 | -7.61 | 86.89 | 78.60 | 45.24 | 49.12 | 20.47 | 18.62 | 1.78 | 0.12 |
Short-term solvency ratios and asset-utilisation metrics
Vertex Pharmaceuticals Incorporated's current ratio of 2.90x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.46x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.99x to 2.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.90 | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 |
| Quick Ratio | 2.46 | 2.46 | 2.35 | 3.78 | 4.66 | 4.30 | 4.18 | 3.49 | 3.32 | 3.14 | 2.21 |
| Cash Ratio | 3.03 | 3.03 | 1.72 | 3.16 | 3.93 | 3.51 | 3.55 | 2.85 | 2.83 | 2.59 | 1.81 |
| Asset Turnover | — | 0.47 | 0.49 | 0.43 | 0.49 | 0.56 | 0.53 | 0.50 | 0.49 | 0.70 | 0.59 |
| Inventory Turnover | 0.97 | 0.97 | 1.27 | 1.71 | 2.35 | 2.56 | 2.62 | 3.27 | 3.29 | 2.46 | 2.71 |
| Days Sales Outstanding | — | 62.43 | 53.31 | 57.82 | 58.94 | 54.78 | 52.08 | 55.55 | 49.07 | 56.61 | 50.49 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vertex Pharmaceuticals Incorporated returns 1.6% to shareholders annually primarily through share buybacks. The earnings yield of 3.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.4% | — | 3.4% | 4.4% | 4.1% | 4.4% | 2.1% | 4.9% | 0.7% | — |
| FCF Yield | 2.5% | 2.7% | — | 3.1% | 5.2% | 4.2% | 4.8% | 2.6% | 2.7% | 1.5% | 1.0% |
| Buyback Yield | 1.6% | 1.7% | 1.5% | 0.6% | 0.2% | 2.7% | 0.9% | 0.3% | 0.8% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.6% | 1.7% | 1.5% | 0.6% | 0.2% | 2.7% | 0.9% | 0.3% | 0.8% | 0.0% | 0.0% |
| Shares Outstanding | — | $258M | $258M | $261M | $259M | $260M | $263M | $261M | $259M | $253M | $245M |
Compare VRTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| VRTXYou | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how VRTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonVertex Pharmaceuticals Incorporated's current P/E ratio is 32.4x. The historical average is 42.7x. This places it at the 75th percentile of its historical range.
Vertex Pharmaceuticals Incorporated's current EV/EBITDA is 26.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.9x.
Vertex Pharmaceuticals Incorporated's return on equity (ROE) is 22.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -31.5%.
Based on historical data, Vertex Pharmaceuticals Incorporated is trading at a P/E of 32.4x. This is at the 75th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Vertex Pharmaceuticals Incorporated has 86.2% gross margin and 39.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Vertex Pharmaceuticals Incorporated's Debt/EBITDA ratio is 0.8x, indicating low leverage. A ratio below 2x is generally considered financially healthy.